Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Sitagliptin Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
CN109096133A reveals high-yield synthesis of Sitagliptin intermediate. Offers cost reduction and supply chain reliability for pharmaceutical manufacturers globally.
Patent CN110914417B reveals high-activity transaminase for chiral amine synthesis, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN111471003B details a cost-effective Negishi coupling route for sitagliptin intermediates, offering high purity and scalable manufacturing solutions.
Discover the improved process for DPP-IV inhibitors reducing costs and enhancing yield. Ideal for reliable pharmaceutical intermediate supply chains and mass production.
Patent CN105218371A reveals a cost-effective Ru-catalyzed route for ethyl 3-hydroxy-4-(2,4,5-trifluorophenyl)butyrate, ensuring high purity and supply reliability.
Novel aminotransferase mutant enables 99% ee sitagliptin intermediate. Robust DMSO tolerance ensures cost reduction in pharma manufacturing.
Patent CN106748888B reveals a safer route for sitagliptin intermediates. Reduces explosive risks and costs for reliable pharmaceutical intermediate suppliers.
Patent CN102503829A reveals a mild Grignard route for sitagliptin intermediates, offering cost-effective and scalable manufacturing solutions for global pharma supply chains.
Patent CN111411095B discloses a novel recombinant (R)-ω-transaminase mutant with high activity and stereoselectivity for efficient sitagliptin intermediate production, ensuring supply chain stability.
High-yield sitagliptin intermediate preparation method patent analysis. Supply chain stability and cost optimization for pharmaceutical manufacturing partners.
Patent CN102093245B details a cost-effective Suzuki coupling route for Sitagliptin intermediates. This method enhances supply chain reliability and reduces dependency on expensive noble metal catalysts for pharmaceutical manufacturing.
Novel enzymatic route for Sitagliptin key intermediate reduces costs and eliminates heavy metals. Ideal for reliable pharmaceutical intermediate suppliers seeking scalable API manufacturing solutions.
Novel transaminase mutant enables high-yield sitagliptin intermediate synthesis with superior stereoselectivity and scalable biocatalytic process efficiency for global supply.
Patent CN117701523A reveals solvent-tolerant transaminase for high-purity sitagliptin intermediate manufacturing with significant supply chain cost reduction.
Patent CN113061594A details a robust immobilized transaminase process for sitagliptin intermediates, offering superior stability and simplified solvent systems for cost-effective API manufacturing.
Novel (R)-ω-transaminase mutant enables high-conversion synthesis of Sitagliptin intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Patent CN107384887A reveals high-purity Sitagliptin synthesis via aminotransferase. Achieves 99% ee and 76% yield, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Novel omega-aminotransferase mutant enables high-yield sitagliptin intermediate production with 99% ee value and reduced solvent constraints for global supply chains.